178 related articles for article (PubMed ID: 24664371)
1. Karyopherin a2 and chromosome region maintenance protein 1 expression in meningiomas: novel biomarkers for recurrence and malignant progression.
Gousias K; Niehusmann P; Gielen GH; Simon M
J Neurooncol; 2014 Jun; 118(2):289-296. PubMed ID: 24664371
[TBL] [Abstract][Full Text] [Related]
2. Nuclear karyopherin a2: a novel biomarker for infiltrative astrocytomas.
Gousias K; Becker AJ; Simon M; Niehusmann P
J Neurooncol; 2012 Sep; 109(3):545-53. PubMed ID: 22772608
[TBL] [Abstract][Full Text] [Related]
3. KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Gousias K; Niehusmann P; Gielen G; Simon M; Boström J
J Clin Neurosci; 2014 Oct; 21(10):1719-24. PubMed ID: 24929863
[TBL] [Abstract][Full Text] [Related]
4. WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma.
Maiuri F; Mariniello G; Guadagno E; Barbato M; Corvino S; Del Basso De Caro M
Acta Neurochir (Wien); 2019 Dec; 161(12):2553-2561. PubMed ID: 31637512
[TBL] [Abstract][Full Text] [Related]
5. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
6. A study of UbcH10 expression and its association with recurrence of meningiomas.
Jiang L; Wang T; Bao Y; Qian J; Wu XJ; Hu GH; Lu YC
J Surg Oncol; 2012 Sep; 106(3):327-31. PubMed ID: 22095464
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II.
Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J
Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study.
Caltabiano R; Barbagallo GM; Castaing M; Cassenti A; Senetta R; Cassoni P; Albanese V; Lanzafame S
J Neurosurg Sci; 2013 Jun; 57(2):139-51. PubMed ID: 23486338
[TBL] [Abstract][Full Text] [Related]
9. [Expression of HER2/neu in meningiomas: an immunohistochemistry and fluorescence in situ hybridization study].
Wang CL; Mei JH; Wang SS; Xu S; Xu LL; Xiong YF
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):156-60. PubMed ID: 20450760
[TBL] [Abstract][Full Text] [Related]
10. Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence.
Csonka T; Murnyák B; Szepesi R; Bencze J; Bognár L; Klekner A; Hortobágyi T
Folia Neuropathol; 2016; 54(2):114-26. PubMed ID: 27543769
[TBL] [Abstract][Full Text] [Related]
11. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
13. Molecular biological determinations of meningioma progression and recurrence.
Linsler S; Kraemer D; Driess C; Oertel J; Kammers K; Rahnenführer J; Ketter R; Urbschat S
PLoS One; 2014; 9(4):e94987. PubMed ID: 24722350
[TBL] [Abstract][Full Text] [Related]
14. Abundant immunohistochemical expression of dopamine D2 receptor and p53 protein in meningiomas: follow-up, relation to gender, age, tumor grade, and recurrence.
Trott G; Pereira-Lima JF; Leães CG; Ferreira NP; Barbosa-Coutinho LM; Oliveira MC
Braz J Med Biol Res; 2015 May; 48(5):415-9. PubMed ID: 25742638
[TBL] [Abstract][Full Text] [Related]
15. Tissue thioredoxin-interacting protein expression predicted recurrence in patients with meningiomas.
Cai Z; Zhang C; Zou Y; Lu C; Hu H; Qian J; Jiang L; Hu G
Int J Clin Oncol; 2017 Aug; 22(4):660-666. PubMed ID: 28243945
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin predicts the behaviour of atypical meningioma.
Lin CK; Tsai WC; Lin YC; Hueng DY
Histopathology; 2012 Jan; 60(2):320-5. PubMed ID: 22211290
[TBL] [Abstract][Full Text] [Related]
17. Differential Tumor Progression Patterns in Skull Base Versus Non-Skull Base Meningiomas: A Critical Analysis from a Long-Term Follow-Up Study and Review of Literature.
Savardekar AR; Patra DP; Bir S; Thakur JD; Mohammed N; Bollam P; Georgescu MM; Nanda A
World Neurosurg; 2018 Apr; 112():e74-e83. PubMed ID: 29258946
[TBL] [Abstract][Full Text] [Related]
18. AKT2 expression in histopathologic grading and recurrence of meningiomas.
Wang Q; Fan SY; Qian J; Wang JY; Lu YC; Hu GH; Luo C
Eur J Surg Oncol; 2014 Sep; 40(9):1056-61. PubMed ID: 24656454
[TBL] [Abstract][Full Text] [Related]
19. Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas.
Kim D; Niemierko A; Hwang WL; Stemmer-Rachamimov AO; Curry WT; Barker FG; Martuza RL; Oh KS; Loeffler JS; Shih HA
J Neurosurg; 2018 Apr; 128(4):1123-1132. PubMed ID: 28621619
[TBL] [Abstract][Full Text] [Related]
20. Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.
Ongaratti BR; Silva CB; Trott G; Haag T; Leães CG; Ferreira NP; Oliveira MC; Pereira-Lima JF
Braz J Med Biol Res; 2016; 49(4):e5125. PubMed ID: 27007654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
